Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The Guía study

Journal of Hypertension

Volumn 20, Issue 10, 2002, Pages 1965-1971

  De Pablos Velasco, Pedro ^a   Martínez Martín, Francisco Javier ^a   Pérez, Fátima Rodríguez ^a   Urioste, Luis Miguel Ruilope ^a   Robles, Rafael García ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Diabetes mellitus; Epidemiology; High blood pressure; Impaired glucose tolerance; Population study

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DIHYDROPINIDINE; PIPERIDINE DERIVATIVE;

ADULT; AGE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SYSTOLIC BLOOD PRESSURE; AGED; AWARENESS; BLOOD PRESSURE; COMPARATIVE STUDY; DIASTOLE; DRUG COMBINATION; DRUG EFFECT; GLUCOSE INTOLERANCE; MIDDLE AGED; SPAIN; SYSTOLE; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AWARENESS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DIASTOLE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PIPERIDINES; PREVALENCE; SPAIN; SYSTOLE; TREATMENT OUTCOME;

EID: 0036808216     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200210000-00015     Document Type: Article

References (44)

1. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309-317.
3. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979; 59:8-13.
4. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites, San Antonio Heart Study, Am J Epidemiol 1990; 131:423-433.
5. Krolewski AS, Warran JH, Cupples A. Hypertension, orthostatic hypotension and microvascular complications of diabetes. J Chron Dis 1985; 38:319-326.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D, Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
8. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
9. Birkenhager WH, Staessen JA, Gasowski J, de Leeuw PW. Effects of antihypertensive treatment on endpoints in the diabetic patients randomised in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol 2000; 13:232-237.
10. Parving HH. Diabetic hypertensive patients. Is this a group in need of particular care and attention? Diabetes Care 1999; 22(suppl 2): B76-B79.
11. de Pablos-Velasco PL, Martinez-Martin FJ, Rodriguez-Pérez F, Ania BJ, Losada A, Betancor P. Prevalence and determinants of diabetes mellitus and glucose intolerance in a Canarian caucasian population. Comparison of the 1997-ADA and the 1985-WHO criteria. The Guia Study. Diabet Med 2001; 18:235-241.
12. WHO. Prevention of Diabetes Mellitus: Report of a WHO Study Group. Geneve, World Health Organization. Second report of the WHO expert committee on diabetes mellitus. Tech Rep Ser 1994; 844.
13. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999; 21:1009-1060.
14. Joint National Committee (JNC-VI). The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157:2413-2446.
15. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 6:24-27.
16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15:539-541.
17. Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Japan: Tohuku University School of Medicine; 1960.
18. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardisation of rates: A new WHO world standard. GPE Discussion Paper Series 31. Geneva: WHO; 2000.
19. Rodriguez Perez JC, Calonge Ramirez S, Bichara Antanios G, Prevalence of ischemic cardiopathy risk factors on the island of Lanzarote. Med Clin (Barc) 1993; 101:45 -50.
20. Compañ Barco L, Vioque J, Quiles J, Hernández-Aguado I, Borrás F. High blood pressure among adults of the Valencian Community (Spain), 1994. A prevalence study. Med Clin (Barc) 1998; 110:328-333.
21. Wolf HK, Tuomihlehto J, Kuulasmaa K, Domarkiene S, Cepaitis G, Molarius A, et al. Blood pressure levels in the 41 populations of the WHO MONICA project. J Hum Hypertens 1997; 11:733-742.
22. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Haemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96:308-311.
23. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001; 103:102-107.
24. Domanski MJ, Sutton-Tyrrell K, Mitchell GF, Faxon DP, Pitt B, Sopko G. Determinants and prognostic information provided by pulse pressure in patients with coronary artery disease undergoing revascularization. Am J Cardiol 2001; 87:675-679.
25. Schurgin S, Rich S, Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 2001; 24:335-338.
26. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999; 17:1065-1072.
27. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999; 100:354-360.
28. Knudsen ST, Poulsen PL, Hansen KW, Ebbehoj E, Bek T, Mogensen CE. Pulse pressure and diurnal blood pressure variation: Association with micro-and macrovascular complications in type 2 diabetes. Am J Hypertens 2002; 15:244-250.
29. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305-313.
30. Marques-Vidal P, Evans AE, Cambou JP, Arveiler D, Luc G, Bingham A, et al. Awareness and control of hypertension and hypercholesterolaemia in France and Northern Ireland. QJM 1997; 90:341-345.
31. Green MS, Peled I. Prevalence and control of hypertension in a large cohort of occupationally active Israelis examined during 1985-1987: The Cordis Study. Int J Epidemiol 1992; 21:676-682.
32. Calvo Gómez C. Situación actual del control de la hipertensión arterial en España. Med Clin (Barc) 2000; 1(suppl 1): 3-7.
33. Coca A, Control de la hipertensión arterial en España. Resultados del estudio Controlpres 95. Hypertension 1995; 12:182-189.
34. Menotti A, Lanti M, Zanchetti A, Puddu PE, Cirillo M, Mancini M, et al. Impact of the Gubbio population study on community control of blood pressure and hypertension. Gubbio Study Research Group. J Hypertens 2001; 19:843-850.
35. Gasse C, Hense HW, Stieber J, Doring A, Liese AD, Keil U. Assessing hypertension management in the community: Trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertens 2001; 15:27-36.
36. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoal-buminuric patients with type 2 diabetes mellitus. A randomised, controlled trial. Ann Intern Med 1998; 128:982-988.
37. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000; 355:253-259.
38. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
39. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
40. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
41. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
42. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955-1964.
43. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension (LIFE): A randomised trial against atenolol. Lancet 2002; 359:1004-1010.
44. Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC Jr, Ciocon JO, et al. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001; 24:654-658.